Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SB-659032 · 2 trials · 1 indication
Percent maximum platelet aggregation following ADP- and collagen-induced aggregation
Urinary 11-dehydrothromboxane B2 and blood CD62 concentrations
| Arm | Type | Description |
|---|---|---|
| SB-659032 | EXPERIMENTAL | 250 mg non-enteric coated SB-659032 |
| Placebo | PLACEBO_COMPARATOR | matched placebo QD for 14 days |
| Name | Type | Description |
|---|---|---|
| SB-659032 | DRUG | - |
| Placebo | DRUG | Matched placebo |
| SB659032 | DRUG | single dose |
Inclusion Criteria: * Healthy adult males between 18 and 55 years of age, inclusive * Body weight greater than 50 kg (110 pounds) and body mass index (BMI) between 19 and 32 where: BMI = weight in kg/(height in meters)2 * A signed and dated written informed consent prior to admission to the study *...
SB-659032 is an investigational small molecule being developed for atherosclerosis, a cardiovascular condition. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied for its effects on platelet function in the context of this disease.
SB-659032 is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The company is conducting early-stage clinical trials to evaluate the drug's safety and effects in healthy volunteers.
SB-659032 is in Phase 1 clinical development. Two Phase 1 trials have been completed, both involving healthy volunteers. The drug is still investigational and has not received regulatory approval for any indication.
SB-659032 has been studied in two completed Phase 1 trials. NCT01745458, a platelet aggregation study with 26 male participants in Australia, and NCT01750827, a study on platelet function with 14 participants in the United States. Both trials enrolled healthy volunteers aged 18 years and older.
SB-659032 is a small molecule that targets platelet function, as indicated by the clinical trials studying its effect on platelet aggregation and function. This mechanism is relevant to atherosclerosis, a condition where platelet activity contributes to disease progression.